SYSTEM AND METHOD FOR A DRUG DELIVERY AND BIOSENSOR PATCH

• US 20170274146A1
• Filed: 04/12/2017
• Published: 09/28/2017
• Est. Priority Date: 07/19/2015
• Status: Active Grant

• Current Assignee: Trilinear Bioventures LLC
• Original Assignee: Sanmina-SCI Corporation
• Inventors: Newberry, Robert Steven, Rodencal, Matthew
• Granted Patent: US 10,155,087 B2
• Time in Patent Office: Days
• CPC Class Codes: A61M 2205/3306 Optical measuring means
• CPC Class Codes: A61M 2205/3584 using modem, internet or bluetooth
• CPC Class Codes: A61M 2205/502 User interfaces, e.g. screens or keyboards
• CPC Class Codes: A61M 2205/52 with memories providing a history of measured variating parameters of apparatus or patient
• CPC Class Codes: A61M 2205/8206 battery-operated
• CPC Class Codes: A61M 2205/8268 Fuel storage cells
• CPC Class Codes: A61M 2230/06 Heartbeat rate only
• CPC Class Codes: A61M 2230/20 Blood composition characteristics
• CPC Class Codes: A61M 2230/30 Blood pressure A61M2230/04 takes precedence
• CPC Class Codes: A61M 2230/42 Rate
• CPC Class Codes: A61M 2230/50 Temperature
• CPC Class Codes: A61M 2230/63 Motion, e.g. physical activity
• CPC Class Codes: A61M 5/14248 of the skin patch type
• CPC Class Codes: A61M 5/145 using pressurised reservoirs, e.g. pressurised by means of pistons
• CPC Class Codes: A61M 5/1723 using feedback of body parameters, e.g. blood-sugar, pressure measurement of body parameters A61B5/00
• CPC Class Codes: A61M 5/3298 Needles arranged in parallel

Abstract

A biosensor detects a medication applied to an upper epidermal layer of skin of a user. The biosensor obtains at periodic intervals a concentration level of the medication in the upper epidermal layer of skin and surrounding tissue of the user. The biosensor may also detect the concentration level of the medication in an arterial blood flow of the patient or obtain a concentration level of a substance in the arterial blood flow, wherein the concentration level of the substance correlates to a first concentration level of the medication. The biosensor may determine an absorption rate of the medication in the upper epidermal layer of skin and surrounding tissue and in an arterial blood flow of the patient from the detected concentration levels of the medication obtained at the periodic intervals.

Claims

1. A system, comprising:

a biosensor configured to detect a medication applied to an upper epidermal layer of skin of a patient, wherein the biosensor is configured to;

obtain at periodic intervals a first concentration level of the medication in the upper epidermal layer of skin and surrounding tissue and in an arterial blood flow of the patient; and

obtain a second concentration level of a substance in the arterial blood flow, wherein the second concentration level of the substance correlates to a first concentration level of the medication.

2. The system of claim 1, wherein the biosensor is further configured to:

determine an absorption rate of the medication in the upper epidermal layer of skin and surrounding tissue and in an arterial blood flow of the patient from the concentration level of the medication obtained at the periodic intervals.

3. The system of claim 1, wherein the biosensor is further configured to:

determine vitals of the patient, wherein the vitals include one or more of;

respiratory rate, heart rate, skin temperature, hemoglobin levels, activity level or blood pressure.

4. The system of claim 1, wherein the biosensor includes at least a photoplethysmograpy (PPG) circuit, wherein the PPG circuit is configured to:

emit light around at least a first wavelength directed at an outer epidermal layer of skin tissue of a patient, wherein the light around at least the first wavelength has a high absorption coefficient for the medication;

emit light around at least a second wavelength directed at the outer epidermal layer of skin tissue of the patient, wherein the light around at least the second wavelength has a high absorption coefficient for the medication;

generate at least a first spectral response for reflected light around the first wavelength; and

generate at least a second spectral response for reflected light around the second wavelength.

5. The system of claim 4, wherein the biosensor further comprises:

a processing circuit configured to obtain the first concentration level of the medication in the upper epidermal layer of skin and surrounding tissue and in the arterial blood flow of the patient at each of the periodic intervals by;

isolating a systolic point and a diastolic point in the first spectral response and obtain a value L<sub>λ

1</sub> using a ratio of the systolic point and the diastolic point in the first spectral response;

isolating a systolic point and a diastolic point in the second spectral response and obtain a value L<sub>λ

2</sub> using a ratio of the systolic point and diastolic point in the second spectral response;

obtaining a value R<sub>λ

1, λ

2</sub> from a ratio of the value L<sub>λ

1</sub> and the value L<sub>λ

2</sub>;

obtaining the first concentration level of the medication in the upper epidermal layer of skin and surrounding tissue and in the arterial blood flow of the patient from at least one calibration table using the value R<sub>λ

1, λ

2</sub>, wherein the calibration table includes a range of R<sub>λ

1, λ

2</sub> values with correlated concentration levels of the medication.

6. The system of claim 1, wherein the biosensor includes at least a PPG circuit, wherein the PPG circuit includes:

a light source configured to emit light directed at the upper epidermal layer of skin of the patient at a plurality of frequencies;

a photodetector circuit configured to detect spectral responses of reflected light at the plurality of frequencies; and

a processing circuit configured to;

process the spectral responses at the plurality of frequencies; and

obtain the first concentration level of the medication in the upper epidermal layer of skin and surrounding tissue and in the arterial blood flow of the patient using the spectral responses.

7. The system of claim 1, further comprising:

a drug delivery system, wherein the drug delivery system is configured to administer the medication to the upper epidermal layer of skin of the patient.

8. The system of claim 7, wherein the drug delivery system includes one or more needles and is configured to administer a dosage of the medication at an administration rate through the one or more needles into the upper epidermal layer of the skin.

9. The system of claim 8, wherein the drug delivery system is configured to alter at least one of the dosage of the medication or the administration rate of the medication or frequency of dosage of the medication in response to at least one of:

the first concentration level of the medication in the upper epidermal layer of skin and surrounding tissue and in an arterial blood flow of the patient and the second concentration level of the substance in the arterial blood flow.

10. The system of claim 1, further comprising:

a wireless transceiver coupled to the biosensor for transmitting the first concentration level and the second concentration level to one or more remote devices.

11. A method, comprising:

detecting biosensor data of a patient using a biosensor, wherein the biosensor data includes one or more of;

respiratory rate, skin temperature, hemoglobin levels, activity level, heart rate or blood pressure;

detecting a medication applied to an upper epidermal layer of the skin;

measuring at periodic intervals by the biosensor a concentration level of the medication in an upper epidermal layer of skin and surrounding tissue and in arterial blood flow of the patient; and

obtaining by the biosensor an absorption rate of the medication from the concentration levels of the medication detected at the periodic intervals.

12. The method of claim 11, further comprising:

detecting by the biosensor a concentration level of a substance in arterial blood flow, wherein the concentration level of the substance correlates to the absorption rate of the medication.

13. The method of claim 12, wherein detecting by the biosensor a concentration level of the substance in arterial blood flow further comprises:

detecting by the biosensor a concentration level of nitric oxide in arterial blood flow.

14. The method of claim 11, wherein measuring at periodic intervals by the biosensor a concentration level of the medication further comprises:

emitting light directed at the upper epidermal layer of skin of the patient at a plurality of frequencies by a photoplethysmograpy (PPG) circuit of the biosensor at each of the period intervals;

detecting spectral responses of reflected light at the plurality of frequencies by a photodetector circuit of the biosensor;

processing the spectral responses at the plurality of frequencies; and

obtaining the concentration level of the medication in the upper epidermal layer of skin and surrounding tissue and in arterial blood flow of the patient.

15. The method of claim 14, wherein processing the spectral responses at the plurality of wavelengths further comprises:

isolating a systolic point and a diastolic point in a first spectral response and obtain a value L<sub>λ

1</sub> using a ratio of the systolic point and the diastolic point in the first spectral response;

isolating a systolic point and a diastolic point in a second spectral response and obtain a value L<sub>λ

2</sub> using a ratio of the systolic point and diastolic point in the second spectral response; and

obtaining a value R<sub>λ

1, λ

2</sub> from a ratio of the value L<sub>λ

1</sub> and the value L<sub>λ

2</sub>; and

obtaining a concentration level of the medication in at least one of;

the upper epidermal layer of skin or surrounding tissue or in the arterial blood flow of the patient of the patient using the value R<sub>λ

1, λ

2</sub> and a calibration table, wherein the calibration table includes a range of R<sub>λ

1, λ

2</sub> values and correlated concentration levels of the medication.

16. The method of claim 11, further comprising:

transmitting a request to a drug delivery system to alter a dosage of the medication in response to at least one of;

the biosensor data or the absorption rate of the medication.

17. The method of claim 11, further comprising:

determining one or more of;

respiratory rate, heart rate, skin temperature, activity level or blood pressure has exceeded a predetermined threshold indicating an allergic reaction; and

transmit an alert to one or more remote devices.

18. The method of claim 11, further comprising:

obtaining position information of the biosensor; and

adjusting operation of the biosensor in response to the position information of the biosensor.

19. The method of claim 14, further comprising:

determining a position of the biosensor on a skin of a patient; and

adjusting the plurality of frequencies of the emitting light directed at the upper epidermal layer of skin of the patient.

20. The method of claim 11, further comprising:

transmitting the biosensor data and the administration rate of the medication to one or more remote devices.

21. A system, comprising:

a biosensor configured to detect a substance applied to an upper epidermal layer of skin of a user, wherein the biosensor is configured to;

obtain at periodic intervals a first concentration level of the substance in the upper epidermal layer of skin; and

obtain at periodic intervals a second concentration level of the substance in surrounding tissue of the user.

22. The system of claim 21, wherein the biosensor comprises:

a photoplethysmograpy (PPG) circuit configured to emit light directed at the upper epidermal layer of skin of the patient at a plurality of frequencies at each of the periodic intervals;

a photodetector circuit configured to detect spectral responses of reflected light at the plurality of frequencies; and

a processing circuit configured to;

process the spectral responses at the plurality of frequencies; and

obtain the first concentration level of the substance in the upper epidermal layer of skin and the second concentration level of the substance in the surrounding tissue of the user using the spectral responses at the plurality of frequencies.